The listed reports indicate varied reactions towards Hologic, Inc. (NASDAQ:HOLX). HOLX showcased substantial momentum in its surgical business, and is set to significantly impact Q3 earnings. Some stock positions in the company have been lowered, including those by Twin Tree Management LP, Texas Permanent School Fund Corp, and GSA Capital Partners LLP. Several insiders including CEO Stephen P. Macmillan and Director Christiana Stamoulis sold substantial shares.
However, many other investors, like Envestnet Portfolio Solutions Inc., TD Asset Management Inc, and Jennison Associates LLC, increased their holdings, suggesting faith in the company’s prospects. Q2 earnings have surpassed estimates, leading to an elevation in HOLX's 2024 view. It witnessed expansion via exemplary M&A, indicating its capacity for growth. Bullish analysts backed this sentiment. Hologic also disclosed plans to acquire Endomagnetics Ltd, a breast surgical guidance company. In addition, its Genius Digital Diagnostics System was launched.
New breast cancer screening guidelines could potentially boost mammography sales. Furthermore, the Acessa Procedure by HOLX secured Anthem Insurance Coverage, and HOLX was set to acquire Biotheranostics for $230M. The company also revealed preliminary revenue results for the first quarter of Fiscal 2024.
Hologic HOLX News Analytics from Thu, 07 Mar 2013 08:00:00 GMT to Sun, 21 Jul 2024 14:21:36 GMT - Rating 5 - Innovation 5 - Information 7 - Rumor -4
